1. PROTAC JAK/STAT Signaling Protein Tyrosine Kinase/RTK Apoptosis PI3K/Akt/mTOR Stem Cell/Wnt MAPK/ERK Pathway
  2. PROTACs EGFR Apoptosis Akt ERK
  3. PROTAC HER2 degrader-1

PROTAC HER2 degrader-1 是一种高的选择性 (IC50 =48.65 nM) 的 HER2 PROTAC 类降解剂,DC50 为 69 nM,Dmax 为 96%。PROTAC HER2 degrader-1 通过持久的 HER2 降解和对下游通路 (AKTERK) 的强力抑制,抑制HER2阳性细胞增殖和肿瘤生长。PROTAC HER2 degrader-1 可用于 HER2 阳性癌症的研究。(粉色:HER2 配体:(HY-177009);黑色:连接子;蓝色:CRBN 配体:(HY-W023573)。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

PROTAC HER2 degrader-1 Chemical Structure

PROTAC HER2 degrader-1 Chemical Structure

CAS No. : 2897640-93-4

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

查看 PROTACs 亚型特异性产品:

查看 EGFR 亚型特异性产品:

查看 Akt 亚型特异性产品:

查看 ERK 亚型特异性产品:

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

PROTAC HER2 degrader-1 is a and highly selective HER2 PROTAC degrader (IC50 = 48.65 nM), with a DC50 of 69 nM and a Dmax of 96%. PROTAC HER2 degrader-1 inhibits HER2-positive cell proliferation and tumor growth through persistent HER2 degradation and potent inhibition of downstream pathways (AKT and ERK). PROTAC HER2 degrader-1 can be used for research of HER2-positive cancers. (Pink: HER2 ligand: (HY-177009); Black: Linker; Blue: CRBN ligand: (HY-W023573)[1].

IC50 & Target[1]

HER2

69 nM (DC50)

CRBN-DDB1

 

体外研究
(In Vitro)

PROTAC HER2 degrader-1 (Compound CH7C4) (0.1-3 μM,24 小时) 可降解 BT-474 细胞中的 HER2,优于 A431 细胞中的 EGFR[1]

PROTAC HER2 degrader-1 (0-10 μM,72 小时) 在 A431 细胞中浓度高达 10 μM 时,对 A431 细胞增殖无抑制作用[1]

PROTAC HER2 degrader-1 可抑制 HER2 驱动的乳腺癌细胞系 BT-474 和 SK-BR-3 以及胃癌细胞系 NCI-N87 的增殖,IC50 值分别为 0.047 nM、0.098 nM 和 0.137 nM[1]

PROTAC HER2 degrader-1 (0-100 nM) 可诱导 BT-474 细胞凋亡,并抑制 BT-474 细胞周期的 G1 期[1]

PROTAC HER2 degrader-1 (0-1 μM) 以浓度依赖性方式在 BT-474 (DC50 = 69 nM,Dmax = 96%) 和 NCI-N87 细胞 (DC50 = 55 nM,Dmax = 94%) 中诱导 HER2 高效降解[1]

PROTAC HER2 degrader-1 (200 nM,0-24 小时) 诱导 BT-474 细胞和 NCI-N87 细胞中HER2 降解并抑制 AKTERK 磷酸化[1]

PROTAC HER2 degrader-1 (200 nM,24 小时) 通过泛素蛋白酶体系统 (UPS) 诱导 BT-474 细胞中泛素化介导的 HER2 降解[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: A431 cells
Concentration: 0.1 μM, 0.3 μM, 1 μM, 3 μM
Incubation Time: 24 h
Result: Induced almost complete degradation of HER2, and a significant hook effect was observed at 3 μM, without significantly affecting EGFR levels in A431 cells.

Apoptosis Analysis[1]

Cell Line: BT-474 cells
Concentration: 0 nM, 10 nM, 50 nM, 100 nM
Incubation Time:
Result: Induced apoptosis (63% at 50 nM) and inhibited G1 cell cycle (84% at 100 nM) in BT-474 cells.

Western Blot Analysis[1]

Cell Line: BT-474 cells, NCI-N87 cells
Concentration: 10 nM, 100 nM, 250 nM, 1000 nM
Incubation Time: 24 h
Result: Induced HER2 degradation and blocked signal transduction in a concentration-dependent manner.
Reduced HER2 autophosphorylation.
Inhibited phosphorylation of key HER2 oncogenic-associated kinases AKT and ERK without affecting their protein levels.

Western Blot Analysis[1]

Cell Line: BT-474 cells, NCI–N87 cells
Concentration: 200 nM
Incubation Time: 0 h, 3 h, 6 h, 12 h, 24 h
Result: Induced significant degradation of HER2 within 3 h.
Induced almost complete degradation of HER2 at 24 h and significantly inhibited AKT and ERK phosphorylation.

Western Blot Analysis[1]

Cell Line: BT-474 cells
Concentration: 200 nM
Incubation Time: 24 h
Result: Degraded HER2, this degradation was completely inhibited after pretreatment with MLN4924 (HY-70062), MG132 (HY-13259), lenalidomide (HY-A0003), and Tucatinib (HY-16069).
体内研究
(In Vivo)

PROTAC HER2 degrader-1 (Compound CH7C4) ( 5 mg/kg,10 mg/kg,静脉注射,每天一次,21 天) 可抑制携带 BT-474 异种移植肿瘤的 BALB/c 裸鼠的肿瘤生长[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude mice bearing BT-474 (i.p., 1 × 107) xenograft tumors[1]
Dosage: 5 mg/kg, 10 mg/kg
Administration: i.v., once a day, 21days
Result: Showed weaker antitumor activity than 10 mg/kg Tucatinib at a dose of 5 mg/kg, with TGI values of 47% and 64%, respectively
Showed superior antitumor activity compared with Tucatinib at a dose of 10 mg/kg (TGI: 73% vs. 64%).
Degraded HER2, and no significant side effects or weight loss were observed during treatment.
分子量

910.03

Formula

C49H55N11O7

CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
PROTAC HER2 degrader-1
目录号:
HY-177008
需求量: